Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

hC Bio: restoring protein function with tRNA therapies

Its sights set on cancer and rare diseases, Boston-based hC Bioscience hopes to take its first engineered tRNA therapy into the clinic next year 

By Danielle Golovin, Biopharma Analyst
September 21, 2023 12:04 AM UTC

hC Bio is among a small set of biotechs pioneering tRNAs as a new therapeutic modality to edit proteins and restore their function without the safety concerns of permanently editing the genome.

The technology behind hC Bioscience Inc. is rooted in a 2019 Nature Communications paper from a group led by co-founder Chris Ahern at the University of Iowa. Leslie Williams, who was an executive in residence at the university, told BioCentury she approached Ahern after reading the paper to argue “this could be a company.”...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

8VC

Arch Venture Partners

CureDuchenne

Hc Bioscience Inc.

Panacea Venture

Taiho Ventures

Takeda Ventures